This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of glatiramer acetate
MSMED_GLATIRAMERACETATE
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
637 |
4. Check minimum number of events
Min. number of events
3
|
637 |
5. Include endpointsNone |
637 |
6. Filter based on genotype QC (FinnGen only) |
637 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of glatiramer acetate
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Other degenerative diseases of the nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 637 | 528 | 109 |
| Unadjusted period prevalence (%) | 0.16 | 0.18 | 0.05 |
| Median age at first event (years) | 38.26 | 37.72 | 40.88 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 564
- Matched controls
- 5639
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
109
Kela drug reimbursment
Multiple sclerosis
9850.4
323.0
545
23
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
2601.0
323.0
501
17
L03AX13
ATC
glatiramer acetate; parenteral
+∞
323.0
564
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
9780.6
323.0
541
19
G35
ICD-10 Finland
Multiple sclerosis
+∞
323.0
564
42
L03AB07
ATC
interferon beta-1a; parenteral
517.4
311.7
284
11
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
31.9
231.9
331
240
N86
ICPC
Multiple sclerosis
296.0
215.2
207
11
H46
ICD-10 Finland
Optic neuritis
163.4
191.9
194
18
164
Kela drug reimbursment
Fingolimod
349.3
177.8
171
7
L03AB08
ATC
interferon beta-1b; parenteral
729.4
169.7
159
*
L04AA27
ATC
fingolimod; oral
630.6
151.2
143
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
134.1
150.2
156
16
353
Kela drug reimbursment
Cladribine and fingolimod
318.2
146.8
143
6
N04BB01
ATC
amantadine; oral
72.8
144.0
162
31
L04AA31
ATC
teriflunomide; oral
289.1
135.5
133
6
L04AX07
ATC
dimethyl fumarate; oral
216.8
133.0
133
8
N07XX09
ATC
[U] dimethyl fumarate; oral
443.4
112.7
109
*
M03BX01
ATC
baclofen; systemic
42.1
98.6
123
37
TAB00
NOMESCO Finland
Lumbar puncture
18.7
98.3
158
115
Z01.0
ICD-10 Finland
Examination of eyes and vision
7.9
85.4
230
451
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
31.2
78.3
105
41
XKD00
NOMESCO Finland
Uroflowmetry
13.1
74.1
138
136
G04BD09
ATC
trospium; oral
43.1
73.5
91
25
XCK00
NOMESCO Finland
Perimetry
12.5
69.9
133
136
N06BA07
ATC
modafinil; oral
139.4
69.7
73
6
XA800
NOMESCO Finland
Neuropsychological investigation
14.8
69.4
121
102
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
43.3
68.7
85
23
2AB04
NOMESCO Finland
NA
196.0
67.7
69
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
29.9
67.3
91
36
G04BD12
ATC
mirabegron; oral
11.7
64.4
126
135
ZX120
NOMESCO Finland
Intravenous
8.4
63.5
154
242
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
556.8
52.4
51
*
H02AB04
ATC
methylprednisolone; systemic
5.4
50.3
176
438
N03AE01
ATC
clonazepam; systemic
9.7
48.1
103
127
G04BD04
ATC
oxybutynin; oral, transdermal
13.7
47.3
84
71
R20.2
ICD-10 Finland
Paraesthesia of skin
7.2
45.9
120
203
XKC03
NOMESCO Finland
Water cystometry
16.9
45.7
74
50
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
22.5
45.2
66
33
UKC02
NOMESCO Finland
Cystoscopy
6.7
45.2
126
233
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
9.1
45.0
100
131
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
127.9
44.5
47
*
G04BD07
ATC
tolterodine; oral
15.0
43.6
74
56
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.8
43.6
77
64
4AA23
NOMESCO Finland
NA
+∞
42.2
40
*
R1250
NOMESCO Finland
Evaluation of functional capability
19.8
40.7
62
35
N03AX12
ATC
gabapentin; oral
4.7
40.4
159
436
G04BD08
ATC
solifenacin; oral
9.7
39.7
84
100
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.5
37.2
121
267
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
7.3
36.0
91
144
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.6
35.7
114
245
TKC22
NOMESCO Finland
Catheterisation instruction
23.2
34.1
49
23
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
120.4
32.0
34
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
10.3
30.8
62
67
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
+∞
30.5
29
*
SPAT1229
SPAT
Assessment of need for aid
7.3
30.3
76
118
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
26.8
29.2
40
16
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.1
29.1
99
226
H53.2
ICD-10 Finland
Diplopia
11.8
28.4
53
49
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
40.1
27.4
34
9
N03AX16
ATC
pregabalin; oral
3.1
27.4
184
757
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
9.7
26.1
54
61
R35
ICD-10 Finland
Polyuria
7.2
26.0
65
100
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
272.4
25.9
26
*
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.1
25.6
59
80
N05CF01
ATC
zopiclone; oral
2.8
25.6
215
1014
G04BD11
ATC
fesoterodine; oral
13.7
24.3
42
33
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
90.7
23.9
26
*
R33
ICD-10 Finland
Retention of urine
8.3
23.1
52
68
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.7
22.0
182
836
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
19.4
22.0
33
18
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
16.6
20.8
33
21
A06AD11
ATC
lactulose; oral
4.0
20.7
88
248
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
8.3
20.5
46
60
J01EA01
ATC
trimethoprim; systemic
2.5
20.4
198
989
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.8
20.0
70
163
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.6
19.8
72
174
L03AB13
ATC
peginterferon beta-1a; parenteral
76.3
19.8
22
*
C10AC01
ATC
colestyramine; oral
8.6
19.3
42
52
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
47.8
19.3
23
5
TKC20
NOMESCO Finland
Catheterisation of bladder
6.0
19.1
54
98
G04CA02
ATC
tamsulosin; oral
5.0
18.1
60
132
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
17.8
17
*
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.1
17.8
111
419
XKD03
NOMESCO Finland
Urethral pressure profilometry
10.6
17.6
34
34
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.0
17.5
58
127
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
8.5
17.0
37
46
N30.0
ICD-10 Finland
Acute cystitis
3.0
16.8
110
427
N29
ICPC
Neurological sympt/complt other
13.2
16.8
29
23
R4110
NOMESCO Finland
Physiotherapy
2.4
16.4
163
808
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
31.1
16.2
21
7
R4120
NOMESCO Finland
Occupational therapy
4.2
15.7
62
162
N06AX16
ATC
venlafaxine; oral
2.6
15.6
132
598
N39.4
ICD-10 Finland
Other specified urinary incontinence
4.5
15.6
56
134
XCD10
NOMESCO Finland
Electrophysiological examination of eye
8.2
15.3
34
44
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
4.4
15.2
56
137
RF120
NOMESCO Finland
NA
12.3
15.2
27
23
R4150
NOMESCO Finland
Neuropsychological rehabilitation
14.5
15.1
25
18
A28
ICPC
Limited function/disability NOS
4.1
15.1
60
158
SPAT1231
SPAT
Assessment of adjustments needed in living environment
15.6
15.0
24
16
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
15.9
14.5
23
15
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.9
14.4
48
106
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
23.0
14.3
20
9
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
54.8
13.9
16
*
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
7.9
13.8
31
41
N03AF01
ATC
carbamazepine; oral, rectal
4.5
13.5
48
114
H53.1
ICD-10 Finland
Subjective visual disturbances
3.8
13.5
59
170
L28
ICPC
Limited function/disability (L)
3.0
13.3
80
292
A02BC02
ATC
pantoprazole; systemic
2.0
13.1
360
2671
L04AA40
ATC
cladribine; oral
51.2
12.9
15
*
N06AB04
ATC
citalopram; systemic
2.2
12.9
151
798
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
71.5
12.6
14
*
L04AX01
ATC
azathioprine; systemic
4.2
12.6
48
122
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
132.8
12.5
13
*
N28
ICPC
Limited function/disability (N)
12.8
12.2
21
17
SPAT1216
SPAT
Assessment of functional ability
3.1
12.2
70
248
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
13.8
12.0
20
15
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
11.9
117
565
G04CA01
ATC
alfuzosin; oral
5.0
11.9
38
81
H02AB07
ATC
prednisone; oral
2.6
11.8
94
405
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
16.8
11.7
18
11
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.6
11.6
90
383
N04BD01
ATC
selegiline; oral
17.5
11.3
17
10
RF420
NOMESCO Finland
NA
8.8
11.1
23
27
N04BC05
ATC
pramipexole; oral
3.6
10.9
49
145
SPAT1262
SPAT
Handing over of treatment supplies
2.5
10.8
91
404
J01CA08
ATC
pivmecillinam; oral
1.8
10.8
288
2053
R42
ICD-10 Finland
Dizziness and giddiness
2.3
10.7
111
548
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.3
10.7
39
96
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
10.6
190
1177
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.0
10.5
146
821
34099
ICD-8 Finland
Multiple sclerosis
112.0
10.5
11
*
G04BD10
ATC
darifenacin; oral
112.0
10.5
11
*
N06AX21
ATC
duloxetine; oral
2.4
9.9
88
403
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
26.5
9.8
13
5
N06AA09
ATC
amitriptyline; systemic
2.9
9.8
61
228
M03BX02
ATC
tizanidine; oral
1.8
9.7
396
3184
U07
ICPC
Urine symptom/complaint other
3.9
9.6
39
106
SPAT1325
SPAT
Vaccination
1.9
9.6
156
928
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
15.4
9.6
15
10
R39.1
ICD-10 Finland
Other difficulties with micturition
6.4
9.5
24
39
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
101.7
9.4
10
*
R5110
SPAT
NA
8.9
9.4
19
22
N03AF02
ATC
oxcarbazepine; oral
5.0
9.3
29
61
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
11.7
9.1
16
14
6BA02
NOMESCO Finland
NA
37.3
9.0
11
*
RF410
NOMESCO Finland
NA
7.6
9.0
20
27
H47.2
ICD-10 Finland
Optic atrophy
24.5
8.9
12
5
H57.1
ICD-10 Finland
Ocular pain
4.0
8.9
34
88
G50.0
ICD-10 Finland
Trigeminal neuralgia
6.1
8.8
23
39
4AA36
NOMESCO Finland
NA
50.8
8.7
10
*
R03CA02
ATC
ephedrine; oral
50.8
8.7
10
*
A06AC01
ATC
ispaghula (psylla seeds); oral
2.0
8.5
123
695
359
Kela drug reimbursment
Mirabegroni
20.4
8.5
12
6
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.4
8.4
71
317
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
8.4
8
*
RF432
NOMESCO Finland
NA
+∞
8.4
8
*
WW400
NOMESCO Finland
Plasmaferesis
+∞
8.4
8
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
5.7
8.1
22
40
J01MA02
ATC
ciprofloxacin; systemic
1.7
7.9
189
1265
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.5
7.9
60
253
H52.1
ICD-10 Finland
Myopia
3.4
7.8
36
110
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.7
7.7
195
1323
G04BDXX
ATC
NA
45.6
7.7
9
*
J05AB01
ATC
aciclovir; systemic
1.8
7.7
141
868
R15
ICD-10 Finland
Faecal incontinence
6.6
7.5
18
28
Z50.1
ICD-10 Finland
Other physical therapy
3.2
7.5
37
120
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.2
7.5
37
120
RS221
NOMESCO Finland
NA
5.7
7.4
20
36
U04
ICPC
Incontinence urine
5.0
7.4
22
45
XCK10
NOMESCO Finland
Photography of fundus of eye
2.7
7.3
47
181
K59.0
ICD-10 Finland
Constipation
3.6
7.2
31
90
SPAT1167
SPAT
Insertion of urinary catheter
8.1
7.1
15
19
KA1AE
NOMESCO Finland
Kidney ultrasound examination
5.3
7.0
20
39
U13
ICPC
Bladder symptom/complaint other
4.4
7.0
24
57
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
6.9
121
730
G04BE03
ATC
sildenafil; oral
14.0
6.9
11
8
SAA02
NOMESCO Finland
Basic examination of mouth
1.6
6.9
392
3280
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
6.8
6.9
16
24
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
6.8
6.9
16
24
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
11.1
6.8
12
11
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.7
6.8
28
79
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
16.9
6.8
10
6
G82.2
ICD-10 Finland
Paraplegia, unspecified
22.8
6.7
9
*
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
22.8
6.7
9
*
RS340
NOMESCO Finland
NA
22.8
6.7
9
*
N06AX11
ATC
mirtazapine; oral
1.7
6.7
179
1231
XF400
NOMESCO Finland
ECG with 12 standard connections
2.2
6.6
65
311
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.2
6.6
63
299
J05AB11
ATC
valaciclovir; oral
2.0
6.6
80
423
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.6
6.5
190
1332
C03CA01
ATC
furosemide; systemic
2.2
6.4
66
323
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
70.6
6.4
7
*
L01BB04
ATC
cladribine; systemic
70.6
6.4
7
*
N07AA03
ATC
distigmine; systemic
70.6
6.4
7
*
Z43.5
ICD-10 Finland
Attention to cystostomy
18.3
6.3
9
5
G37.8
ICD-10 Finland
Other specified demyelinating diseases of central nervous system
+∞
6.3
6
*
119
Kela drug reimbursment
Trigeminal neuralgia or glossofaryngeusneuralgia
27.0
6.2
8
*
R27.0
ICD-10 Finland
Ataxia, unspecified
27.0
6.2
8
*
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.2
6.1
59
280
J01XX05
ATC
methenamine; oral
12.7
6.1
10
8
U08
ICPC
Urinary retention
12.7
6.1
10
8
R51.80
ICD-10 Finland
Headache
1.8
6.0
102
606
K59.09
ICD-10 Finland
Constipation, unspecified
3.1
6.0
30
99
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.1
6.0
30
99
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
110
10
132.75
218.14
3.1
2.3
—
—
—
0
0
155
94
21.47
191.81
1.2
1.1
—
—
—
0
0
87
33
30.38
128.77
2.5
2.3
14.4
10.8
%
1.00
41
16
83
34
27.92
119.41
4.5
2.6
471.0
444.0
e6/l
0.21
72
28
210
388
7.58
117.08
3.8
2.5
9.4
10.3
g/l
3.68
194
360
142
181
9.81
108.68
1.9
1.6
0.0
0.0
iu/ml
—
8
22
517
2579
6.33
85.39
15.1
5.5
25.6
29.5
%
14.96
511
2445
512
2555
6.12
83.88
14.8
5.3
59.6
56.8
%
7.31
507
2426
63
31
22.44
83.87
2.5
2.3
—
—
—
0
0
541
3012
6.28
72.33
16.1
8.4
3.6
4.0
e9/l
5.58
528
2675
62
42
16.25
70.82
5.0
2.4
914.2
796.9
e6/l
0.40
40
15
49
26
20.33
62.85
1.2
1.2
1760.3
1764.3
miu/ml
0.01
49
26
41
15
29.14
60.62
6.3
3.1
—
—
—
0
0
289
1154
3.75
58.06
5.8
2.4
0.1
0.4
e6/l
2.34
242
843
68
76
9.90
56.45
1.2
1.1
—
—
—
0
0
536
3296
4.95
54.29
10.3
3.5
72.5
480.0
e6/l
0.50
11
33
408
2142
3.52
51.28
2.7
2.3
97.6
74.6
nmol/l
28.33
388
2005
49
42
12.56
48.61
1.0
1.1
—
—
—
0
0
49
48
10.98
44.50
1.0
1.1
222.3
227.1
mg/l
0.07
35
40
50
51
10.55
44.15
1.1
1.1
51.6
29.2
mg/l
3.24
36
39
187
660
3.60
43.55
4.8
2.2
0.9
1.0
e6/l
0.19
115
345
171
611
3.46
38.59
5.1
2.2
5.8
4.0
e6/l
0.64
100
297
419
2606
2.78
32.66
6.7
3.0
0.0
0.0
estimate
0.80
97
489
415
2574
2.76
32.43
9.0
4.1
0.0
0.0
estimate
0.50
96
512
413
2573
2.72
31.68
6.8
2.9
0.0
0.0
estimate
0.00
94
500
63
131
5.23
29.19
1.1
1.5
435.2
422.0
mg/l
0.14
57
121
32
8
42.05
26.06
1.1
1.0
—
—
—
0
0
379
2414
2.41
25.41
5.6
5.4
9.4
9.6
umol/l
0.34
361
2279
39
58
7.10
25.32
1.0
1.1
—
—
—
0
0
39
61
6.75
24.17
1.1
1.1
—
—
—
0
0
54
118
4.91
23.56
1.3
1.8
641.2
172.9
e6/l
0.50
44
97
54
118
4.91
23.56
1.1
1.7
8.0
5.0
e6/l
0.95
43
93
38
63
6.35
22.26
1.1
1.1
—
—
—
0
0
50
110
4.85
21.62
4.1
4.1
3.7
4.4
e9/l
1.80
50
110
31
43
7.53
21.37
1.0
1.1
0.9
1.1
u/l
—
8
23
50
112
4.76
21.16
4.2
4.5
61.3
58.1
%
1.11
50
112
113
443
2.89
20.78
2.5
2.0
5765.9
4250.7
u/l
0.14
35
183
18
13
14.22
19.42
2.2
2.2
—
—
—
0
0
129
564
2.61
19.11
2.3
2.0
29.4
29.5
s
0.10
122
551
62
206
3.23
15.07
1.5
1.3
—
—
—
0
0
304
2036
1.94
14.90
7.5
2.9
—
—
—
0
0
44
119
3.90
14.58
1.1
1.4
3.7
3.6
mmol/l
0.15
38
111
209
1312
1.88
11.84
8.5
3.2
0.0
0.0
estimate
1.08
95
508
15
5
30.66
11.69
1.1
1.2
—
—
—
0
0
78
339
2.48
11.45
2.5
1.7
—
—
—
0
0
467
5356
0.52
11.16
3.4
3.6
1.5
1.5
mmol/l
0.24
428
5122
443
5153
0.54
10.86
3.1
3.3
1.3
1.3
mmol/l
1.19
412
4921
262
1801
1.77
10.81
4.5
4.5
37.4
37.1
g/l
0.36
242
1694
477
5414
0.53
10.36
3.7
3.9
3.0
2.9
mmol/l
1.00
437
5165
464
3790
1.83
10.19
7.0
6.7
73.8
74.0
u/l
0.04
434
3593
174
1076
1.85
10.09
7.7
3.1
1.0
1.0
kg/l
0.43
27
144
473
5373
0.54
10.03
3.5
3.6
4.9
4.9
mmol/l
0.88
439
5161
348
2650
1.69
9.51
4.6
4.2
6.1
6.4
mmol/l
2.85
328
2424
44
159
2.90
9.26
1.4
1.6
—
—
—
0
0
622
5765
4.35
8.65
18.0
8.5
27.7
26.1
u/l
1.76
613
5641
584
5280
2.27
7.84
13.4
9.9
139.8
139.6
mmol/l
1.37
576
5157
20
48
4.27
7.78
1.2
1.6
—
—
—
0
0
585
5301
2.27
7.67
13.5
10.0
3.9
3.9
mmol/l
0.44
575
5164
256
1883
1.60
7.44
5.3
3.1
28.6
29.0
u/l
0.08
246
1800
593
5426
2.34
7.20
14.3
10.1
18.8
18.6
mg/l
0.05
469
4120
102
588
1.87
7.19
1.6
1.7
—
—
—
0
0
472
4051
1.64
6.79
5.0
2.9
49.9
39.1
u/l
1.52
456
3904
71
384
1.96
6.05
1.6
1.6
—
—
—
0
0
71
397
1.89
5.49
1.6
1.6
—
—
—
0
0
38
770
0.46
5.27
1.5
1.6
—
—
—
0
0
258
2016
1.47
5.18
6.8
5.9
1.2
1.2
mmol/l
0.27
218
1707
225
1771
1.42
4.13
6.7
5.3
1.2
1.2
mmol/l
0.22
204
1627
419
4660
0.71
4.07
4.0
4.2
37.0
38.1
mmol/mol
1.64
389
4456
123
863
1.53
4.07
1.5
1.4
22.4
21.2
nmol/l
0.35
107
772
84
539
1.64
4.06
2.4
2.5
6.7
5.0
umol/l
0.74
77
455
13
38
3.47
3.92
1.1
1.1
—
—
—
0
0
165
1241
1.44
3.85
1.9
2.0
197.9
158.4
u/l
0.29
158
1183
102
698
1.55
3.77
2.6
2.8
333.5
350.4
ng/l
0.03
45
369
204
1621
1.38
3.43
1.9
1.8
99.1
98.0
pmol/l
0.11
101
900
541
5038
1.49
3.23
12.9
8.4
96.7
91.8
ml/min/173m2
8.70
470
4123
34
180
1.94
3.16
2.7
2.0
11.5
5.5
iu/l
1.03
15
71
76
1080
0.66
2.86
1.2
1.3
1.7
11.6
u/ml
4.41
26
472
28
148
1.93
2.65
11.6
2.5
0.6
0.7
%
0.62
28
143
46
285
1.66
2.59
8.6
3.4
1.9
1.8
mmol/l
0.15
41
231
12
44
2.76
2.56
1.5
1.2
—
—
—
0
0
46
291
1.63
2.41
8.6
3.4
5.8
5.8
kpa
0.06
46
284
83
1111
0.71
2.25
1.3
1.3
9.8
24.7
iu/ml
6.26
18
374
17
82
2.10
2.08
1.2
1.2
—
—
—
0
0
46
304
1.55
2.04
1.1
1.3
264.7
234.3
miu/ml
0.17
17
159
6
15
4.03
2.04
1.0
1.1
—
—
—
0
0
6
15
4.03
2.04
1.0
1.1
79.7
98.9
%
—
6
15
21
365
0.56
1.88
1.3
1.5
—
—
—
0
0
478
5051
0.79
1.86
3.4
3.5
5.6
5.7
mmol/l
0.66
437
4783
22
375
0.57
1.84
1.3
1.5
—
—
—
0
0
21
116
1.84
1.80
1.6
1.8
3.4
3.9
g/l
1.48
15
91
21
116
1.84
1.80
1.6
1.8
—
—
—
0
0
21
116
1.84
1.80
1.6
1.8
6.6
7.3
g/l
1.06
15
97
18
323
0.54
1.80
1.3
1.7
5.1
2.8
mg/l
—
9
216
37
241
1.57
1.77
9.8
2.5
4.7
4.9
kpa
0.18
37
236
175
1476
1.26
1.77
2.3
2.5
51.3
55.2
u/l
1.21
161
1389
7
24
2.94
1.72
1.1
1.2
—
—
—
0
0
40
268
1.53
1.70
2.1
1.7
—
—
—
0
0
20
111
1.83
1.70
1.5
1.8
2.9
3.0
g/l
0.23
15
92
166
1404
1.25
1.63
1.3
1.3
0.9
1.8
u/ml
0.98
39
407
78
598
1.35
1.62
1.6
1.6
1096.9
1183.5
nmol/l
0.42
62
483
5
14
3.59
1.62
2.8
1.9
47.5
52.7
ug/l
—
5
14
64
846
0.73
1.62
1.8
1.8
1.5
1.3
%
1.48
58
778
437
4641
0.81
1.61
3.6
3.8
—
—
—
0
0
26
160
1.65
1.58
1.8
1.9
—
—
—
0
0
78
604
1.33
1.53
2.4
2.2
2.6
2.4
g/l
1.10
73
559
107
867
1.28
1.51
1.4
1.6
479.7
26209082.1
pmol/l
1.05
97
786
24
147
1.66
1.49
1.9
1.7
—
—
—
0
0
58
432
1.38
1.46
2.6
2.3
24.8
33.3
u/l
2.07
43
363
5
16
3.14
1.44
1.2
1.1
—
—
—
0
0
412
3847
1.20
1.41
2.9
3.7
9.3
9.2
mm/h
0.06
381
3641
9
40
2.27
1.40
1.0
1.2
—
—
—
0
0
84
667
1.30
1.39
2.5
2.2
15.6
14.8
umol/l
0.35
77
610
95
1163
0.78
1.39
1.8
2.2
4284.8
4682.7
umol/l
0.03
89
1057
26
167
1.58
1.36
1.5
1.4
28.7
23.0
u/l
0.37
18
139
16
90
1.80
1.34
1.3
4.0
—
329.0
—
0
10
15
83
1.83
1.32
4.7
3.5
28.9
25.3
mg/l
—
9
55
41
294
1.42
1.30
11.2
6.8
1.2
1.3
mmol/l
0.07
41
285
13
69
1.90
1.29
1.3
2.7
—
983.0
—
0
6
20
122
1.66
1.28
1.0
1.2
—
—
—
0
0
5
18
2.79
1.28
2.4
2.7
7.9
18.1
umol/l
—
5
18
12
62
1.95
1.28
1.4
1.8
—
—
—
0
0
23
344
0.66
1.18
1.3
1.4
—
—
—
0
0
46
343
1.37
1.18
12.3
10.7
1.0
1.2
inr
—
10
58
11
57
1.95
1.17
1.2
1.4
9.7
11.4
mmol/l
—
5
9
23
343
0.66
1.17
1.3
1.4
—
—
—
0
0
10
50
2.02
1.17
1.2
1.1
259.6
290.6
mg/l
—
10
45
47
353
1.36
1.16
6.6
9.5
0.6
1.0
mmol/l
0.18
33
273
52
397
1.34
1.16
2.4
2.6
—
—
—
0
0
23
341
0.66
1.14
1.3
1.4
—
—
—
0
0
23
341
0.66
1.14
1.3
1.4
—
—
—
0
0
0
36
0.00
1.14
0.0
1.7
—
—
—
0
0
28
193
1.47
1.11
1.7
2.4
67.8
74.6
ng/l
0.14
21
170
7
31
2.27
1.10
1.4
1.1
—
—
—
0
0
87
718
1.25
1.08
2.2
2.8
572.4
550.0
ng/l
0.03
72
582
13
74
1.77
1.07
1.1
1.2
—
—
—
0
0
13
74
1.77
1.07
1.1
1.2
—
—
—
0
0
531
5130
1.21
1.03
6.2
4.8
1.6
1.9
mu/l
0.88
507
4906
15
91
1.66
1.01
1.6
2.3
377.3
267.0
ug/l
0.25
15
79
7
35
2.01
1.00
2.4
1.7
2.6
0.9
u/field
—
7
27
12
198
0.60
0.97
1.2
1.4
82.3
117.1
pmol/l
0.25
12
192
0
32
0.00
0.95
0.0
9.6
—
44.8
—
0
13
66
537
1.26
0.95
2.6
2.3
26.0
24.7
%
0.24
52
456
17
109
1.57
0.94
1.0
1.3
1.3
4.3
u/ml
—
6
35
518
5340
0.84
0.94
21.2
10.9
39.5
40.2
%
1.17
385
4495
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
30
2.01
0.87
1.0
1.2
—
—
—
0
0
10
167
0.59
0.86
1.3
1.2
—
—
—
0
0
21
297
0.70
0.86
1.5
1.8
—
—
—
0
0
17
112
1.53
0.85
1.0
1.3
3.0
6.3
u/ml
—
5
43
10
166
0.60
0.84
1.3
1.2
—
—
—
0
0
129
1137
1.17
0.83
2.0
1.9
—
—
—
0
0
17
248
0.68
0.82
1.4
1.6
—
—
—
0
0
17
114
1.50
0.80
1.1
1.2
263.3
215.6
u/ml
0.26
12
69
107
1221
0.85
0.79
1.9
2.1
—
—
—
0
0
168
1516
1.15
0.79
1.6
1.5
—
—
—
0
0
0
26
0.00
0.78
0.0
1.0
—
40.6
—
0
26
28
369
0.75
0.76
1.7
2.1
87.1
78.9
ml/min/173m2
0.95
11
143
26
195
1.35
0.70
1.2
1.3
—
—
—
0
0
9
58
1.56
0.70
1.2
1.3
—
—
—
0
0
93
1060
0.86
0.69
5.5
3.8
3.7
10.4
mg/mmol
2.34
62
678
50
603
0.81
0.69
1.3
1.5
—
—
—
0
0
16
110
1.47
0.69
1.0
1.1
—
—
—
0
0
10
61
1.65
0.69
1.0
1.5
—
—
—
0
0
19
137
1.40
0.65
2.9
3.0
24.9
24.6
mmol/l
0.24
19
131
8
49
1.64
0.62
1.0
1.0
—
—
—
0
0
10
63
1.60
0.62
1.0
1.1
—
—
—
0
0
5
30
1.67
0.61
1.6
2.9
—
—
—
0
0
57
483
1.20
0.60
5.6
5.0
—
—
—
0
0
71
614
1.18
0.60
1.2
1.3
35.0
27.4
iu/l
0.90
63
523
124
1119
1.13
0.60
2.2
2.0
2.9
2.7
mg/l
0.35
106
975
0
22
0.00
0.59
0.0
1.5
—
8.3
—
0
22
12
172
0.69
0.57
2.4
1.6
—
—
—
0
0
6
39
1.54
0.53
1.0
1.3
—
—
—
0
0
58
500
1.18
0.53
3.4
3.4
29.8
31.6
%
0.93
50
382
72
632
1.16
0.52
3.0
3.0
0.8
0.8
mmol/l
0.01
67
605
7
107
0.65
0.49
1.1
1.3
—
—
—
0
0
21
164
1.29
0.47
6.1
9.7
24.4
24.0
mmol/l
0.20
21
157
49
567
0.85
0.47
1.4
1.8
—
—
—
0
0
15
111
1.36
0.47
1.9
1.6
—
—
—
0
0
33
395
0.83
0.46
1.6
1.5
—
—
—
0
0
8
56
1.43
0.42
1.4
1.4
—
—
—
0
0
76
683
1.13
0.41
2.0
2.3
2.4
2.4
mmol/l
0.79
60
601
254
2423
1.08
0.41
3.7
3.8
—
—
—
0
0
5
33
1.52
0.41
1.2
1.5
7.2
6.9
u/l
—
5
28
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.0
—
593.8
—
0
12
0
17
0.00
0.40
0.0
1.0
—
33.9
—
0
11
161
1509
1.09
0.40
2.7
2.6
86.0
27.9
ng/l
0.50
76
704
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
14
182
0.76
0.39
1.1
1.1
0.6
2.1
u/ml
—
5
70
16
124
1.30
0.39
1.4
1.0
0.9
2.5
u/ml
—
6
65
14
107
1.32
0.37
1.2
1.4
—
—
—
0
0
67
741
0.89
0.36
1.6
1.9
—
—
—
0
0
6
45
1.34
0.34
1.2
1.4
—
—
—
0
0
156
1473
1.08
0.33
2.1
3.1
2.3
2.3
mmol/l
0.85
132
1352
6
47
1.28
0.32
2.2
3.2
41.8
64.1
u/ml
—
6
47
16
128
1.26
0.32
1.3
1.3
—
—
—
0
0
42
371
1.14
0.31
1.1
1.1
—
—
—
0
0
26
221
1.18
0.31
2.7
2.8
5.3
5.1
kpa
0.68
26
208
456
4472
1.07
0.31
5.4
4.2
14.4
14.3
pmol/l
0.66
428
4247
17
206
0.82
0.29
1.5
2.0
—
—
—
0
0
7
57
1.23
0.29
1.6
1.1
—
—
—
0
0
131
1237
1.07
0.28
1.8
1.7
0.9
0.7
mg/l
0.29
84
920
12
151
0.79
0.28
1.6
2.5
9.0
10.0
mg/l
0.20
12
140
10
76
1.32
0.28
1.7
1.2
—
—
—
0
0
9
73
1.24
0.25
1.1
1.4
—
—
—
0
0
104
1098
0.94
0.22
1.8
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
8
101
0.79
0.21
1.1
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
5.1
—
—
—
0
0
19
219
0.86
0.20
1.5
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
273
2796
0.96
0.19
3.0
2.8
85.0
77.9
ug/l
0.20
258
2667
6
53
1.13
0.18
1.2
1.4
—
—
—
0
0
18
202
0.89
0.14
1.2
1.5
—
—
—
0
0
8
97
0.82
0.14
1.0
1.3
—
—
—
0
0
28
304
0.92
0.13
7.7
3.1
1.2
1.2
mmol/l
0.38
23
265
28
304
0.92
0.13
2.0
4.2
2.5
7.3
ug/l
2.11
19
229
20
181
1.11
0.12
1.1
1.1
—
—
—
0
0
36
337
1.07
0.11
1.4
1.6
—
—
—
0
0
11
95
1.16
0.11
2.3
4.0
3.7
3.8
mmol/l
0.12
11
87
127
1303
0.97
0.10
1.6
1.7
1.5
1.4
mmol/l
0.64
105
1149
24
223
1.08
0.09
1.3
1.5
—
—
—
0
0
6
55
1.09
0.09
1.2
1.2
—
—
—
0
0
6
55
1.09
0.09
1.2
1.2
—
—
—
0
0
6
56
1.07
0.08
1.2
1.2
—
—
—
0
0
6
56
1.07
0.08
1.2
1.2
—
—
—
0
0
6
56
1.07
0.08
1.2
1.2
—
—
—
0
0
7
64
1.09
0.08
1.1
1.4
—
—
—
0
0
7
81
0.86
0.07
1.0
1.2
—
—
—
0
0
7
85
0.82
0.07
3.0
2.4
—
—
—
0
0
152
1495
1.02
0.06
1.6
1.6
—
—
—
0
0
30
315
0.95
0.06
1.7
2.3
0.6
0.7
ug/l
0.16
16
150
44
427
1.03
0.04
2.5
3.3
22.4
21.3
%
0.12
17
141
27
281
0.96
0.04
1.4
1.5
—
—
—
0
0
12
111
1.08
0.04
1.9
1.8
—
—
—
0
0
17
164
1.04
0.00
1.1
1.2
—
2.7
—
0
20
35
356
0.98
0.00
1.5
1.5
—
—
—
0
0
11
114
0.96
0.00
1.0
1.1
—
—
—
0
0
55
546
1.01
0.00
1.3
1.2
230.4
164.3
iu/ml
0.43
20
232
6
62
0.97
0.00
1.5
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
6
62
0.97
0.00
1.5
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
6
64
0.94
0.00
1.5
1.3
—
—
—
0
0
6
64
0.94
0.00
1.5
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
36.0
—
0
6
9
99
0.91
0.00
1.1
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
63
0.95
0.00
1.5
1.3
—
—
—
0
0
6
61
0.98
0.00
1.5
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
0.00
1.2
1.3
23.1
32.1
nmol/l
—
6
47
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.6
—
22.2
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
7
70
1.00
0.00
1.3
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
67.0
—
0
6
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_GLATIRAMERACETATE – Use of glatiramer acetate
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).